Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies

S Frantz, MJ Hundertmark… - European heart …, 2022 - academic.oup.com
Most patients survive acute myocardial infarction (MI). Yet this encouraging development
has certain drawbacks: heart failure (HF) prevalence is increasing and patients affected tend …

Neprilysin inhibitors in heart failure: the science, mechanism of action, clinical studies, and unanswered questions

B Bozkurt, AP Nair, A Misra, CZ Scott, JH Mahar… - Basic to Translational …, 2023 - jacc.org
This article provides a contemporary review and a new perspective on the role of neprilysin
inhibition in heart failure (HF) in the context of recent clinical trials and addresses potential …

Heart failure: an update from the last years and a look at the near future

M Riccardi, AM Sammartino, M Piepoli… - ESC heart …, 2022 - Wiley Online Library
In the last years, major progress occurred in heart failure (HF) management. Quadruple
therapy is now mandatory for all the patients with HF with reduced ejection fraction. Whilst …

[PDF][PDF] 射血分数保留的心力衰竭研究新进展

张班, 刘晓刚, 胡立群 - 临床心血管病杂志, 2022 - whuhzzs.com
射血分数保留的心力衰竭(HFpEF) 患者通常有多种合并症, 包括高血压, 糖尿病, 肥胖等.
随着人口老龄化, 其在心力衰竭(心衰) 中所占比例正逐年升高. 由于治疗缺乏循证医学证据支持 …

Effect of neprilysin inhibition on Alzheimer disease plasma biomarkers: a secondary analysis of a randomized clinical trial

WS Brum, KF Docherty, NJ Ashton, H Zetterberg… - JAMA …, 2024 - jamanetwork.com
Methods| In a post hoc exploratory analysis of a 52-week randomized clinical trial
(NCT03552575), we examined the effect of sacubitril/valsartan vs valsartan (ie, neprilysin …

Impact of sacubitril/valsartan compared with ramipril on cardiac structure and function after acute myocardial infarction: the PARADISE-MI echocardiographic substudy

AM Shah, B Claggett, N Prasad, G Li, M Volquez… - Circulation, 2022 - Am Heart Assoc
Background: Angiotensin-converting enzyme inhibitors attenuate left ventricular (LV)
enlargement after acute myocardial infarction (AMI). Preclinical data suggest similar benefits …

Effect of Sacubitril/Valsartan vs valsartan on left atrial volume in patients with Pre–Heart failure with preserved ejection fraction: the PARABLE randomized clinical trial

M Ledwidge, JD Dodd, F Ryan, C Sweeney… - JAMA …, 2023 - jamanetwork.com
Importance Pre–heart failure with preserved ejection fraction (pre-HFpEF) is common and
has no specific therapy aside from cardiovascular risk factor management. Objective To …

Angiotensin receptor-neprilysin inhibitor (ARNI) and cardiac arrhythmias

H Sutanto, D Dobrev, J Heijman - International journal of molecular …, 2021 - mdpi.com
The renin-angiotensin-aldosterone system (RAAS) plays a major role in cardiovascular
health and disease. Short-term RAAS activation controls water and salt retention and causes …

Efficacy and safety of early initiation of Sacubitril/Valsartan in patients after acute myocardial infarction: a meta‐analysis

J Zhao, Y Zeng, X Shen - Clinical Cardiology, 2021 - Wiley Online Library
Some randomized controlled trials have compared the effectiveness and safety outcomes
between early initiation of Sacubitril/Valsartan and angiotensin‐converting enzyme …

Update on cardioprotective strategies for STEMI: focus on supersaturated oxygen delivery

RA Kloner, JL Creech, GW Stone, WW O'Neill… - Basic to Translational …, 2021 - jacc.org
Despite the fact that door-to-balloon times have been greatly reduced, the rates of death and
the incidence of heart failure in patients with ST-segment elevation myocardial infarction (MI) …